Literature DB >> 10393610

Familial aggregation in Behçet's disease: high frequency in siblings and parents of pediatric probands.

I Koné-Paut1, I Geisler, B Wechsler, S Ozen, H Ozdogan, M Rozenbaum, I Touitou.   

Abstract

OBJECTIVE: To examine familial aggregation of Behçet's disease (BD) in pediatric compared with non-pediatric patients.
METHODS: A retrospective study was conducted to analyze data collected from 572 patients with BD in whom the diagnosis was made with criteria defined by the International Study Group for BD. The age of attaining criteria (the age at which the patient met the study group criteria) was evaluated for each patient. Recurrence risks were calculated for the pediatric group from information provided by 45 families.
RESULTS: Of the 505 patients from whom the age of attaining criteria could be ascertained, 106 showed definitive BD before the age of 16 years and were considered as pediatric patients with BD; the other 399 were classified as non-pediatric patients. Thirteen of the 106 pediatric patients (12.3%) and only 9 of the 399 non-pediatric patients (2.2%) had relatives affected by BD. This excess of familial cases in the pediatric group compared with the non-pediatric group was significant (P <.0001, chi2 analysis). Moreover, the mean age of attaining criteria in familial cases (17. 95 years [SD = 8.62]) was significantly lower than in sporadic cases (27.28 years [SD = 11]; P <.0001, Student t test). The recurrence risk among siblings and parents who met the International Study Group criteria was 0.1.
CONCLUSION: Our data support the hypothesis of a genetic component in the pathogenesis of BD, and we propose the inclusion of familial history in the definition of pediatric BD.

Entities:  

Mesh:

Year:  1999        PMID: 10393610     DOI: 10.1016/s0022-3476(99)70333-1

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  24 in total

1.  Alliteration in medicine: a puzzling profusion of p's.

Authors:  G F Hayden
Journal:  BMJ       Date:  1999 Dec 18-25

Review 2.  Clinical Immunology Review Series: an approach to the patient with recurrent orogenital ulceration, including Behçet's syndrome.

Authors:  M T Keogan
Journal:  Clin Exp Immunol       Date:  2008-12-11       Impact factor: 4.330

3.  Genetic variants in the JAK1 gene confer higher risk of Behcet's disease with ocular involvement in Han Chinese.

Authors:  Shengping Hou; Jian Qi; Qi Zhang; Dan Liao; Qi Li; Ke Hu; Yan Zhou; Aize Kijlstra; Peizeng Yang
Journal:  Hum Genet       Date:  2013-05-15       Impact factor: 4.132

Review 4.  Role of genetics in pediatric rheumatology.

Authors:  Eda Tahir Turanlı; Elif Everest; Ayşe Balamir; Aslı Kireçtepe Aydın; Özgür Kasapçopur
Journal:  Turk Pediatri Ars       Date:  2017-09-01

Review 5.  Behçet syndrome: from pathogenesis to novel therapies.

Authors:  Gianluigi Mazzoccoli; Angela Matarangolo; Rosa Rubino; Michele Inglese; Angelo De Cata
Journal:  Clin Exp Med       Date:  2014-12-02       Impact factor: 3.984

6.  Familial aggregation of Behçet's disease in Turkey.

Authors:  A Gül; M Inanç; L Ocal; O Aral; M Koniçe
Journal:  Ann Rheum Dis       Date:  2000-08       Impact factor: 19.103

7.  Genetic susceptibility to Behçet's syndrome is associated with NRAMP1 (SLC11A1) polymorphism in Turkish patients.

Authors:  Omer Ateş; Levent Dalyan; Gulen Hatemi; Vedat Hamuryudan; Aysegul Topal-Sarikaya
Journal:  Rheumatol Int       Date:  2008-11-08       Impact factor: 2.631

8.  Familial Behçet's disease.

Authors:  Sema Yilmaz; Kadriye Akar Cimen
Journal:  Rheumatol Int       Date:  2009-07-03       Impact factor: 2.631

Review 9.  Is Behçet's disease a 'class 1-opathy'? The role of HLA-B*51 in the pathogenesis of Behçet's disease.

Authors:  M Giza; D Koftori; L Chen; P Bowness
Journal:  Clin Exp Immunol       Date:  2017-10-06       Impact factor: 4.330

Review 10.  Behçet's Disease and Nervous System Involvement.

Authors:  Murat Kürtüncü; Erdem Tüzün; Gulsen Akman-Demir
Journal:  Curr Treat Options Neurol       Date:  2016-05       Impact factor: 3.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.